Trial Profile

A Phase 1/2 Study of the Safety and Efficacy of LX2006 Gene Therapy in Participants With Cardiomyopathy Associated With Friedreich's Ataxia

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Aug 2026 According to a LEXEO Therapeutics media release , potential BLA submission under accelerated approval pathway planned in first half of 2028.
18 Jun 2026 Results presented in the LEXEO Therapeutics Media Release.
18 Jun 2026 According to a LEXEO Therapeutics media release, company announced that key results from Phase I/II studies of LX2006 gene therapy in Friedreich ataxia (FA) have been published in the Journal of the American Medical Association (JAMA) Cardiology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com